Back to News
Market Impact: 0.18
Johnson & Johnson Receives CE Marking for ACUVUE OASYS MAX Reusable Contact Lenses
Source: Business Wire
Product LaunchesHealthcare & BiotechTechnology & Innovation
Johnson & Johnson received CE Marking for ACUVUE OASYS MAX 2-Week, a new reusable contact lens incorporating its proprietary MAX technologies. The authorization supports commercialization in CE-mark jurisdictions and expands J&J Vision's contact-lens product portfolio, but the announcement provides no revenue, sales outlook, or launch-timing details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
JNJ0.65
More News
- J&J prostate cancer drug shows promising tumor responses in early trial
- Protagonist Therapeutics: The Opt-Out That Turned A Biotech Into A Royalty Compounder
- Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer
- AI funding fears rattle Wall Street. Here's how we're adjusting our portfolio
- Here’s the ‘core economic flaw’ in the AI bull case as stock and bond trades unravel, according to a top economist
- Biotech stocks are surging. How investors can play the new drug innovation boom